Abstract
Metastatic pheochromocytomas and paragangliomas (MPPs) present clinicianswith three major challenges: scarcity, complexity of characterization, and heterogeneous behavior and prognosis. As with the treatment for all neuroendocrine tumors, the control of hormonal symptoms and tumor growth is the main therapeutic objective in MPP patients. A significant number of MPP patients still die from uncontrolled hormone secretion. In addition, the management of MPPs remains palliative. Steps forward include proper characterization of MPP patients at large cancer referral centerswithmultidisciplinary teams; improved strategies to stratify patients prognostically; and implementation of trials within national and international networks. Progress in the molecular characterization and staging of MPPs constitutes the basis for significant treatment breakthroughs.
Original language | English (US) |
---|---|
Pages (from-to) | R111-R122 |
Journal | European journal of endocrinology |
Volume | 171 |
Issue number | 3 |
DOIs | |
State | Published - Sep 1 2014 |
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology